Unknown Manufacturer
Lixisenatide is a GLP-1 receptor agonist used for the management of type 2 diabetes mellitus.
Lixisenatide is a GLP-1 receptor agonist used for the management of type 2 diabetes mellitus.
The activation of the GLP-1 receptor by lixisenatide results in the activation of adenylyl cyclase. This increases the concentration of cyclic adenosine monophosphate in the cell leading to the activation of protein kinase A (PKA) as well as Epac1 and Epac2. PKA, Epac1, and Epac2 are involved the in release of Ca2+ from the endoplasmic reticulum which is known as the "amplification" pathway which increases insulin release when the triggering pathway is activated. By activating this amplification pathway lixisenatide increases glucose stimulated insulin secretion.
Lixisenatide is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type II diabetes mellitus. It is also available in combination with insulin glargine for the same indication.
1 associated conditions
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
